In Vitro and in Vivo Activities of AIC292, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5320-5329

  Wildum, Steffen ^a   Paulsen, Daniela ^a   Thede, Kai ^b   Ruebsamen Schaeff, Helga ^a   Zimmermann, Holger ^a  

^a AiCuris GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (3 CHLORO 4 FLUORO PHENYL) 5 (3 CHLORO 5 FLUORO PHENYL) 1H PYRAZOLE 3 CARBON]IMIDAZOLIDIN 4 ONE; ABACAVIR; AIC 292; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG TOLERABILITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE; XENOGRAFT;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HETEROGRAFTS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMIDAZOLIDINES; MICE; MUTATION; PYRAZOLES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84885936519     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01377-13     Document Type: Article

References (44)

1. Jonckheere H, Anne J, De CE. 2000. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 20:129-154.
2. De Clercq E. 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6:1001-1018.
3. Zhou Z, Lin X, Madura JD. 2006. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect. Disord. Drug Targets 6:391-413.
4. Clavel F, Hance AJ. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
5. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. 2012. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 56:5000-5008.
6. Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Bethune MP. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 14:103-109.
7. Tang MW, Shafer RW. 2012. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72:e1-e25. doi:10.2165/11633630- 000000000-00000.
8. Fulco PP, McNicholl IR. 2009. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 29:281-294.
9. Fernandez-Montero JV, Vispo E, Anta L, de Mendoza C, Soriano V. 2012. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin. Pharmacother. 13:1007-1014.
10. Best BM, Goicoechea M. 2008. Efavirenz -still first-line king? Expert Opin. Drug Metab. Toxicol. 4:965-972.
11. Jayaweera DT, Espinoza L, Castro J. 2008. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors. Expert Opin. Pharmacother. 9:3083-3094.
12. Waters L, John L, Nelson M. 2007. Non-nucleoside reverse transcriptase inhibitors: a review. Int. J. Clin. Pract. 61:105-118.
13. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van CE, Picchio G, Rimsky LT. 2010. TMC278, a nextgeneration NNRTI, active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
14. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. 2004. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983. Rev. Invest. Clin. 56:126-129.
15. Wain-Hobson S, Vartanian JP, Henry M, Chenciner N, Cheynier R, Delassus S, Martins LP, Sala M, Nugeyre MT, Guetard D. 1991. LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science 252:961-965.
16. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
17. Schulz TF, Whitby D, Hoad JG, Corrah T, Whittle H, Weiss RA. 1990. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J. Virol. 64:5177-5182.
18. Buckheit RW, Jr, Roberson JL, Lackman-Smith C, Wyatt JR, Vickers TA, Ecker DJ. 1994. Potent and specific inhibition of HIV envelopemediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10:1497-1506.
19. Ruebsamen-Waigmann H, Willems WR, Bertram U, von Briesen H. 1989. Reversal of HIV-phenotype to fulminant replication on macrophages in perinatal transmission. Lancet 334:1155-1156.
20. von Briesen H, Andreesen R, Esser R, Brugger W, Meichsner C, Becker K, Ruebsamen-Waigmann H. 1990. Infection of monocytes/ macrophages by HIV in vitro. Res. Virol. 141:225-231.
21. Golz S, Kalthof B, Markova S, Frank L, Vysotski E. May 2002. Isolated luciferases lu164, lual and lu22, and the use of the same. Patent WO/2002/ 042469.
22. Markova SV, Golz S, Frank LA, Kalthof B, Vysotski ES. 2004. Cloning and expression of cDNA for a luciferase from the marine copepod Metridia longa. A novel secreted bioluminescent reporter enzyme. J. Biol. Chem. 279:3212-3217.
23. Paulsen D, Welker R. April 2008. Nucleic acid molecule useful for characterizing antiretroviral agents comprises a coding sequence for an HIV mutant capable of replication in vitro and a coding sequence for a luciferase. Patent DE102006046423A1.
24. Buckheit RW, Jr, Swanstrom R. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retroviruses 7:295-302.
25. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Uberla K. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13:71-80.
26. Margot NA, Miller MD. 2005. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir. Ther. 10:343-348.
27. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205.
28. Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, Distefano DJ, Hazuda DJ, Miller MD. 2009. Antiviral activity of MK-4965: a novel non-nucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53:2424-2431.
29. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.
30. Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ. 2010. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and non-nucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 54:1973-1980.
31. Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW. 2012. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Antimicrob. Agents Chemother. 56:4522-4524.
32. McNamara PJ, Alcorn J. 2002. Protein binding predictions in infants. AAPS PharmSci. 4:E4. doi:10.1208/ps040104.
33. Oie S, Jacobson MA, Abrams DI. 1993. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J. Acquir. Immune Defic. Syndr. 6:531-533.
34. Buonaguro L, Tornesello ML, Buonaguro FM. 2007. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81:10209-10219.
35. Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT. 2010. HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir. Ther. 15:985-991.
36. Ciccozzi M, Santoro MM, Giovanetti M, Andrissi L, Bertoli A, Ciotti M. 2012. HIV-1 non-B subtypes in Italy: a growing trend. New Microbiol. 35:377-386.
37. Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD. 2010. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with non-nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 54:4812-4824.
38. Perrin L, Kaiser L, Yerly S. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
39. Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ. 2010. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to non-nucleoside RT inhibitors. J. Virol. 84:9817-9830.
40. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De CE, Heneine W. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.
41. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19:825-835.
42. Boffito M, Sciole K, Raiteri R, Bonora S, Hoggard PG, Back DJ, Di PG. 2002. Alpha 1-acid glycoprotein levels in human immunodeficiency virusinfected subjects on antiretroviral regimens. Drug Metab. Dispos. 30:859-860.
43. Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Perez-Elias MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C. 2013. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 27:81-85.
44. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Bethune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503-514.